Dustin Jasmer
Family · Layton, UTNPI 1275979841
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,400 of the $66,887 with a category attached, or 78.3%. 25 manufacturers reported payments, led by Tris Pharma Inc at 49.5% of the total. Among family clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 588 payments — averaging $113.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$33K
- AbbVie$29K
- Supernus Pharmaceuticals, Inc.$926
- Alkermes, Inc.$730
- Otsuka America Pharmaceutical, Inc.$419
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$375
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$52,40078%
- Travel & lodging$5,1338%
- Food & beverage$9,29914%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 109 | $33,126 |
| AbbVie | 208 | $29,262 |
| Supernus Pharmaceuticals, Inc. | 47 | $926 |
| Alkermes, Inc. | 44 | $730 |
| Otsuka America Pharmaceutical, Inc. | 28 | $419 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $375 |
| Ironshore Pharmaceuticals Inc. | 20 | $313 |
| Lundbeck LLC | 14 | $243 |
| Axsome Therapeutics, Inc. | 14 | $240 |
| Corium, LLC | 12 | $240 |
| Vanda Pharmaceuticals Inc. | 10 | $178 |
| Adlon Therapeutics L.p. | 14 | $164 |
| Sunovion Pharmaceuticals Inc. | 16 | $135 |
| Johnson & Johnson | 5 | $94 |
| Idorsia Pharmaceuticals US Inc | 5 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| Neurocrine Biosciences, Inc. | 2 | $61 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $26 |
| Lilly USA, LLC | 2 | $25 |
| Braeburn Inc. | 1 | $25 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dyanavel XR$30,905
- Quillivant$30,701
- Quillichew ER$30,701
- VRAYLAR$26,534
- QELBREE$293
How this compares
$66,887 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 13 | $733 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $682 |
Paid to pharmacies, not to this prescriber.
Other family in Layton
- Scott CrepeauLayton$16K
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$395K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.